Phase 3 trial, 322 patients with EGFR-variant nonsquamous NSCLC after EGFR-TKI: adding ivonescimab to pemetrexed–carboplatin improved overall survival (key secondary end point; median 16.8 vs 14.1 months, HR 0.74). Grade ≥3 adverse events: 67.1% vs 54.7%.
RCTn = 322
HARMONi-A Study Investigators et al. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial